⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
globenewswire.com
RARE
RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm
globenewswire.com
RARE
Pomerantz LLP Informs Shareholders of Securities Class Action Against Ultragenyx Pharmaceutical Inc. – RARE
accessnewswire.com
RARE
RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
RARE
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
globenewswire.com
RARE
ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
globenewswire.com
RARE
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE
prnewswire.com
RARE
Form 8-K
sec.gov
RARE
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
globenewswire.com
RARE
Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
globenewswire.com
RARE